In several transgenic mouse models of AD, genetic and pharmacological treatments that increase CatB activity led to the significant lowering of Aβ42 levels [31, 35, 37–41] as well as to reductions in the cellular and behavioral disease parameters [31, 35, 37, 38, 41]. This evidence concerns the gene TYRP1 and Alzheimer disease.